



```

439
•
CCGCGGCCCGAATTCGAGCTCGGTACCCGGGGATCCTCTAGTCAGCTG
Sac II      EcoR I      Kpn I      BamH I      Pvu II
488
•
ACGCGTGCTAGCGCGGCCGCATCGATAAGCTTGTGCGACGATATCTCTAGA
Mlu I  Nhe I  Eag I  Not I  Cla I  Hind III  Sal I  EcoR V  Xba I
                                   Acc I

```

**Map and Multiple Cloning Site (MCS) of pTRE2 Vector.** Unique restriction sites are in bold.

### Description

pTRE2 is a response plasmid that can be used to express a gene of interest (Gene X) in Clontech's Tet-On™, Tet-Off™, RevTet-On™, and RevTet-Off™ Gene Expression Systems and Cell Lines (1). The Tet Expression Systems and Cell Lines give researchers ready access to the tetracycline-regulated expression systems described by Gossen & Bujard (2; Tet-Off) and Gossen *et al.* (3; Tet-On). pTRE2 contains an MCS immediately downstream of the Tet-responsive  $P_{hCMV^*-1}$  promoter. cDNAs or genes inserted into the MCS will be responsive to the tTA and rTA regulatory proteins in the Tet-Off and Tet-On systems, respectively.  $P_{hCMV^*-1}$  contains the Tet response element (TRE), which consists of seven copies of the 42-bp tet operator sequence (*tetO*). The TRE is just upstream of the minimal CMV promoter ( $P_{minCMV}$ ), which lacks the enhancer that is part of the complete CMV promoter. Consequently,  $P_{hCMV^*-1}$  is silent in the absence of binding of TetR or rTetR to the *tetO* sequences. Note that the cloned insert must have an initiating ATG codon. In some cases, addition of a Kozak consensus ribosome binding site (4) may improve expression levels; however, many cDNAs have been efficiently expressed in Tet systems without the addition of a Kozak sequence. pTRE2-Gene X plasmids should be cotransfected with the pTK-Hyg Vector (not included) to permit selection of stable transfectants. pTRE2 was originally described as pUHD10-3 in reference 5.

The pTRE2-Luc Control Vector, packaged with the pTRE2 Vector, contains an additional 1649 bp encoding firefly luciferase inserted into the MCS. This vector can be used as a reporter of induction efficiency using standard luciferase detection reagents. It is not intended as a cloning vector.

### Location of features

- $P_{\text{hCMV}^{-1}}$  Tet-responsive promoter: 7–438  
Tet response element (TRE): 7–318  
Location of seven *tetO* 18-mers: 15–33; 57–75; 99–117; 141–159; 183–201; 225–243 & 257–275  
Fragment containing  $P_{\text{min CMV}}$ : 319–438  
TATAA box: 341–348
- Multiple cloning site (MCS): 470–537
- Fragment containing  $\beta$ -globin poly A signal: 538–1705
- Fragment containing Col E1 origin of replication: 1907–2550
- Ampicillin resistance gene ( $\beta$ -lactamase): 3558–2697

### Propagation in *E. coli*

- Suitable host strains: DH5 $\alpha$  and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100  $\mu\text{g/ml}$ ) to *E. coli* hosts.
- *E. coli* replication origin: Col E1

### Primer Locations

- pTRE2 5' Sequencing/PCR Primer (#9130-1): 376–392
- pTRE2 3' Sequencing/PCR Primer (#9130-1): 630–649

### References

1. HT1080 Cell Line & pTRE2 Vector (January 1999) *CLONTECHniques XIV*(1):23.
2. Gossen, M. & Bujard, H. (1992) *Proc. Natl. Acad. Sci USA* **89**:5547–5551.
3. Gossen, M., *et al.* (1995) *Science* **268**:1766–1769.
4. Kozak, M. (1987) *Nucleic Acids Res.* **15**:8125–8148.
5. Resnitzky, D., *et al.* (1994) *Mol. Cell. Biol.* **14**:1669–1679.

### Note:

The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

### Notice to Purchaser

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of Clontech Laboratories, Inc.

Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent Nos. 5,464,758 & 5,814,618, which are proprietary to TET Systems Holding GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from IP Merchandisers in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems Holding GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems Holding GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to IP Merchandisers, Inc. For license information, please contact:

Hans Peter Kneubuehl  
TET Systems Holding GmbH & Co. KG  
Im Neuenheimer Feld 582  
69120 Heidelberg  
Germany  
Tel +49 6221 588 04 00  
Fax +49 6221 588 04 04  
eMail: [kneubuehl@tet-systems.de](mailto:kneubuehl@tet-systems.de)  
or use our electronic licensing request form via  
[http://www.tetsystems.com/main\\_inquiry.htm](http://www.tetsystems.com/main_inquiry.htm)

Clontech, Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc.  
Clontech is a Takara Bio Company. ©2006